Fig. 9From: Body mass index-associated molecular characteristics involved in tumor immune and metabolic pathwaysSignature of BMI-related clinically actionable genes and FDA-approved drugs. The target relationship between FDA-approved anti-cancer drugs and corresponding clinically actionable genes (left) and the observed BMI-associated clinically actionable genes in each tumor type (right). A different color of symbols indicated different shapes of symbols indicated BMI groups and molecular modelsBack to article page